Elevation Oncology Inc. (ELEV)
0.78
0.06 (8.24%)
At close: Jan 14, 2025, 3:59 PM
0.79
0.43%
Pre-market Jan 15, 2025, 07:15 AM EST
undefined% (undefined)
| Bid | 0.79 |
| Market Cap | 46.37M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.81 |
| Volume | 6,126,951 |
| Avg. Volume (20D) | 1,708,409 |
| Open | 0.72 |
| Previous Close | 0.72 |
| Day's Range | 0.71 - 0.86 |
| 52-Week Range | 0.50 - 5.83 |
| Beta | undefined |
About ELEV
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is bas...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 29
Stock Exchange NASDAQ
Ticker Symbol ELEV
Website https://elevationoncology.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ELEV stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 792.40% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 days ago ·
Source
+10.79%
Elevation Oncology shares are trading higher after...
Unlock content with
Pro Subscription
5 months ago ·
Source
-63.37%
Elevation Oncology shares are trading lower. The company reported Q2 financial results.
